Sentences with phrase «vaccine candidates against»

MHRP's expansion of research activities into Mozambique provides scientists the opportunity to test future vaccine candidates against the predominant HIV subtype (C) circulating in this part of the world.

It provides a specific way to benchmark HIV - 1 vaccine candidates against the one partially efficacious vaccine to date.»

In order to move forward they made pioneering technological breakthroughs as well, all of which have resulted in the most promising vaccine candidate against malaria to date.

Not exact matches

GSK has 15 vaccine candidates in development against diseases, including shingles, RSV, GBS, and chronic obstructive pulmonary disease (COPD) exacerbations.

Based on their findings, they urge that «mosquito saliva and enhancing antibodies thus need to be considered when developing vaccines and drugs against dengue,» and specifically suggest that «animal models of dengue and pre-clinical validation of dengue vaccine candidates should be evaluated in the combined presence of mosquito saliva and enhancing antibodies.»

«It was not known whether any of these vaccines could provide protection against the new outbreak West African Makona strain of Ebola Zaire currently circulating in Guinea,» said John Eldridge, Chief Scientific Officer - Vaccines at Profectus Biosciences, Inc. «Our findings show that our candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virusvaccines could provide protection against the new outbreak West African Makona strain of Ebola Zaire currently circulating in Guinea,» said John Eldridge, Chief Scientific Officer - Vaccines at Profectus Biosciences, Inc. «Our findings show that our candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virusVaccines at Profectus Biosciences, Inc. «Our findings show that our candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virusvaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virus.»

Attempts at using live dengue viruses to develop a dengue fever vaccine have often led to an imbalance in immunity to the four dengue serotypes — for instance, one recent candidate had lower efficacy against serotype 2.

Researchers have developed a candidate vaccine against Ebola, one of the world's deadliest viruses.

«We observed rapid and durable protective immunity without adverse events, and so we think this candidate vaccine represents a promising strategy for the global fight against Zika virus,» said senior author Drew Weissman, MD, PhD, a professor of Infectious Disease at Penn. «We hope to start clinical trials in 12 to 18 months.»

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.

A study published on May 7th in PLOS Pathogens now shows that a candidate vaccine can induce long - lasting immunity against the parasite in mice.

The reliably high percentage of those who develop viremia following exposure to this challenge virus is another advantage — when most or all volunteers develop viremia or other signs of infection, clinical trials can enroll relatively small numbers of people but still achieve answers to such questions as whether a candidate vaccine protects against infection, she noted.

«The findings from this trial are very encouraging to those of us who have spent many years working on vaccine candidates to protect against dengue, a disease that is a significant burden in much of the world and is now endemic in Puerto Rico,» said Stephen Whitehead, Ph.D., of NIH's National Institute of Allergy and Infectious Diseases (NIAID).

The study showed that single shots of either vaccine candidate protected mice against subsequent Zika challenge.

In a previously published paper, Barouch and colleagues, including Colonel Nelson L. Michael, MD, PhD, director of the Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) and Stephen Thomas, MD, Upstate Medical University, State University of New York, demonstrated that three different vaccine candidates provided robust protection against Zika virus in both mice and rhesus monkeys.

«New candidate vaccines against the plague.»

Candidate vaccines against Ebola or malaria — one of which recently received an important stamp of approval in Europe — should definitely be used if they are safe and effective, he says, but they could lead to more virulent pathogens.

Researchers plan to assess the new modified antigen against other candidates in advanced strep throat vaccine tests in nonhuman primates beginning later this year in Atlanta, Georgia, funded by the National Health and Medical Research Council of Australia.

«We previously showed that adenovirus vector - based HIV - 1 vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical Vaccine Research at BIDMC and professor of medicine at Harvard Medical School.

Researchers at the University of Maryland and Duke University have designed a novel protein - sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV.

«But the ability of the vaccine candidate to raise substantial antibodies against the sugar shield in only two months is encouraging; other studies took up to four years to achieve similar results.

When injected into rabbits, the vaccine candidate stimulated antibody responses against the sugar shield in four different HIV strains.

In April 2017, Moderna published human data for its mRNA vaccine technology in Molecular Therapy, which showed that its first prophylactic vaccine candidate, mRNA - 1440 — an mRNA prophylactic vaccine against avian H10N8 influenza — induced high levels of immunogenicity and was safe and well tolerated.

Prothena's candidate vaccines seem to have had no effect on the relatively mild loss of SN DA neurons in this model, but to have afforded substantial protection against the more profound losses in the striatum.

IDRI's current vaccine candidate (a fusion of four recombinant proteins and IDRI's proprietary adjuvant) is effective against MDR TB strains.

WCBS 880 AM — A «Promising Lead» in Fight Against Pancreatic Cancer - April 4, 2012 Early results from a clinical trial at CINJ show stable disease in pancreatic cancer for certain candidates following vaccine treatment.

In 2009, a vaccine candidate studied in a trial of over 16,000 individuals in Thailand was the first to modestly protect against HIV infection.

Preclinical studies of vaccine candidates have typically shown post-infection virologic control, but protection against acquisition of infection has previously only been reported using less rigorous viral challenges.

The Wistar Institute was awarded a $ 1,494,972 grant by the Bill & Melinda Gates Foundation to advance a DNA - based vaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Revaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer ReVaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Research.

These vaccine candidates warrant further clinical evaluation of efficacy against the blood - stage P. vivax parasite.

Current topics include vaccine efficacy testing and immune correlates of TB, AMA1 as a malaria blood stage vaccine candidate in clinical development and development of new drugs active against malaria hypnozoites.